1 in 4 with substance-induced psychosis later develops schizophrenia.
Several employees at SKDE are co-authors of a new scientific article that shows that one in four individuals admitted for treatment of substance-induced psychosis later receives a diagnosis of schizophrenia.
Photo: Colourbox
For individuals with cannabis psychosis, research shows that one in three later receives a diagnosis of schizophrenia. This implies that many who are given a diagnosis in psychiatry (substance-induced psychosis) eventually develop another, more serious mental illness.
This may be due to substance use triggering severe mental illness, but it also suggests that those who experience a psychosis as a result of substance use have a high vulnerability to schizophrenia as well. It can also be debated whether we attribute too much weight to substance use and that it takes too long for patients with such disorders to receive the help they need, the authors of the article point out.
The article was published on 3 May in one of the leading psychiatric journals in the world, The American Journal of Psychiatry. Ina Heiberg, Bjarne Jacobsen, and Anne Høye from SKDE are co-authors alongside first author Eline Borger Rognli (OUS) and Jørgen Gustav Bramness (FHI).
You can read more about the findings on the news page of Oslo University Hospital.
You can find the link to the article in the American Journal of Psychiatry here.